Mechanism of Action — Passive Scaffold vs. Active Oxygen Delivery
Active Biological Stimulus
Delivers molecular oxygen continuously to the wound bed — directly stimulating angiogenesis, collagen synthesis, fibroblast proliferation, and bacterial suppression. Addresses the root cause of chronicity: hypoxia.
Passive Structural Support
Provide a biological scaffold and modulate excess matrix metalloproteinases (MMPs). Effective at supporting tissue regeneration — but require adequate oxygenation to work. Do not address wound hypoxia.
Clinical Outcomes — Healing Rates vs. Standard of Care
| Wound Type · 12 Weeks | RashEndZ™ TOT Complete Closure |
Collagen / ECM Complete Closure |
Advantage |
|---|---|---|---|
| Diabetic Foot Ulcers | 50–60% | 40–50% | TOT +10–15% |
| Pressure Ulcers | 40–55% area reduction · Wk 6 | 60–70% area reduction · Wk 4 | Collagen faster early |
| Venous Leg Ulcers | 45–60% | 25–40% | TOT +15–20% |
| IAD / MASD / Perineal | IRB-confirmed resolution | Not indicated | TOT only option |
| Stage 4 Pressure Ulcers | >80% area reduction · 7 wks (case) | Adjunct to NPWT / surgery | TOT primary capable |
Scope of Use — Where Each Therapy Can Be Applied
Every Wound · Every Location · Every Setting
DFU · VLU · Pressure injuries Stage 2–4 · IAD · MASD · Perineal · Surgical · Acute. Pediatric through geriatric. Hospital · LTC · Home health · Community. One protocol, all settings.
Stage 3–4 Deep Wounds · Adjunct Only
Most effective in Stage 3–4 chronic wounds with viable wound beds post-debridement. Not indicated for Stage 1 or intact skin. Not used for perineal/IAD. Always adjunct — not standalone therapy.
Cost Per Dressing — Direct Procurement Comparison
Continuous 24/7 TOT · 24–72 hr change interval · No secondary equipment
60 sq in coverage · Same price · Perineal and large wound applications
64 sq in coverage · Passive adjunct only · No oxygen delivery
Dressing Cost + Existing O₂ Infrastructure
No capital equipment. No rental fees. Leverages oxygen already present in every care setting. Incremental O₂ cost in facilities effectively $0. Standard supply chain procurement.
Premium Unit Cost × Frequent Changes
$80–700+ per dressing depending on type, size, and sterility. Change frequency every 2–3 days. No equipment cost — but premium unit cost compounds across a treatment episode.
Strategic Position — Replacement or Complement
Primary Therapy — Replaces Advanced Dressings
RashEndZ™ is applied where advanced dressings are currently used — and delivers superior or equivalent clinical outcomes at a fraction of the cost. In Stage 3–4 wounds, it can serve as a primary dressing rather than an adjunct, reducing total protocol complexity.
Adjunct Only — Requires Full Protocol Stack
Collagen and ECM dressings are never standalone. They require debridement, infection control, offloading, compression, or NPWT depending on wound type. They add cost on top of a full protocol — RashEndZ™ simplifies and replaces that layer.
Advanced dressings are clinically validated and widely adopted — but they are passive, expensive, adjunct-only solutions that do not address wound hypoxia. RashEndZ™ continuous topical oxygen therapy treats the biological root cause of wound chronicity, achieves equivalent or superior healing outcomes across major wound types, covers indications that advanced dressings cannot (perineal, IAD, MASD), and does so at a cost that is 4–7× lower per dressing — using infrastructure already in place everywhere. For health systems, payers, and wound care programs, the economic and clinical case is clear.